CNM Publications 2009 to Present

Found 95 results
Author Title Type [ Year(Asc)]
2013
Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi G-P, Ruoslahti E.  2013.  De novo design of a tumor-penetrating peptide.. Cancer Res. 73(2):804-12.
Zanuy D, Sayago FJ, Revilla-López G, Ballano G, Agemy L, Kotamraju VRamana, Jiménez AI, Cativiela C, Nussinov R, Sawvel AM et al..  2013.  Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing.. J Comput Aided Mol Des. 27(1):31-43.
Sánchez-Martín D, Sanz L, Ruoslahti E, Álvarez-Vallina L.  2013.  In vivo selection of tumor-specific antibodies.. Oncotarget. 4(10):1547.
Grewal PK, Aziz PV, Uchiyama S, Rubio GR, Lardone RD, Le D, Varki NM, Nizet V, Marth JD.  2013.  Inducing host protection in pneumococcal sepsis by preactivation of the Ashwell-Morell receptor.. Proc Natl Acad Sci U S A. 110(50):20218-23.
Lo JH, von Maltzahn G, Douglass J, Park J-H, Sailor MJ, Ruoslahti E, Bhatia SN.  2013.  Nanoparticle amplification via photothermal unveiling of cryptic collagen binding sites.. J Mater Chem B Mater Biol Med. 1(39):5235-5240.
Orr SL, Le D, Long JM, Sobieszczuk P, Ma B, Tian H, Fang X, Paulson JC, Marth JD, Varki N.  2013.  A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins.. Glycobiology. 23(3):363-80.
Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E.  2013.  Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.. Mol Ther. 21(12):2195-204.
Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, M Martín T, Molina-Privado I, Ruppen-Cañás I et al..  2013.  Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.. Proc Natl Acad Sci U S A. 110(34):13791-6.
Cho M, Oh SSoo, Nie J, Stewart R, Eisenstein M, Chambers J, Marth JD, Walker F, Thomson JA, H Soh T.  2013.  Quantitative selection and parallel characterization of aptamers.. Proc Natl Acad Sci U S A. 110(46):18460-5.
Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VRamana, Basu S et al..  2013.  Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy.. Cancer Res. 73(23):6987-97.
Järvinen TAH, Ruoslahti E.  2013.  Targeted Antiscarring Therapy for Tissue Injuries.. Adv Wound Care (New Rochelle). 2(2):50-54.
Teesalu T, Sugahara KN, Ruoslahti E.  2013.  Tumor-penetrating peptides.. Front Oncol. 3:216.
Kolhar P, Anselmo AC, Gupta V, Pant K, Prabhakarpandian B, Ruoslahti E, Mitragotri S.  2013.  Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium.. Proc Natl Acad Sci U S A. 110(26):10753-8.
Rothman A, Davidson S, Wiencek RG, Evans WN, Restrepo H, Sarukhanov V, Ruoslahti E, Williams R, Mann D.  2013.  Vascular histomolecular analysis by sequential endoarterial biopsy in a shunt model of pulmonary hypertension.. Pulm Circ. 3(1):50-7.
2012
Sturgill ER, Aoki K, Lopez PHH, Colacurcio D, Vajn K, Lorenzini I, Majić S, Yang WHo, Heffer M, Tiemeyer M et al..  2012.  Biosynthesis of the major brain gangliosides GD1a and GT1b.. Glycobiology. 22(10):1289-301.
Luni C, Marth JD, Doyle FJ.  2012.  Computational modeling of glucose transport in pancreatic β-cells identifies metabolic thresholds and therapeutic targets in diabetes.. PLoS One. 7(12):e53130.
Yang WHo, Nussbaum C, Grewal PK, Marth JD, Sperandio M.  2012.  Coordinated roles of ST3Gal-VI and ST3Gal-IV sialyltransferases in the synthesis of selectin ligands.. Blood. 120(5):1015-26.
Karmali PPrakash, Chao Y, Park J-H, Sailor MJ, Ruoslahti E, Esener SC, Simberg D.  2012.  Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles.. Mol Pharm. 9(3):539-45.
Teesalu T, Sugahara KN, Ruoslahti E.  2012.  Mapping of vascular ZIP codes by phage display.. Methods Enzymol. 503:35-56.
Ruoslahti E.  2012.  Peptides as targeting elements and tissue penetration devices for nanoparticles.. Adv Mater. 24(28):3747-56.
Chao Y, Makale M, Karmali PPrakash, Sharikov Y, Tsigelny I, Merkulov S, Kesari S, Wrasidlo W, Ruoslahti E, Simberg D.  2012.  Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains.. Bioconjug Chem. 23(5):1003-9.
Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS.  2012.  Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.. J Control Release. 161(3):804-12.
Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, Li DY, Ruoslahti E, Komatsu M.  2012.  Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels.. Cancer Cell. 22(2):235-49.
Ren Y, Cheung HWing, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF et al..  2012.  Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.. Sci Transl Med. 4(147):147ra112.
Brunquell C, Biliran H, Jennings S, Ireland SKale, Chen R, Ruoslahti E.  2012.  TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells.. Mol Cancer Res. 10(11):1482-95.

Pages